Skip to main content

Table 5 The clinical trials of CAR-NK cell-based therapy for hematological malignancies and solid tumors

From: Natural killer cells: a promising immunotherapy for cancer

Cancer type ClinicalTrials.gov Identifier Initial time Phase N Primary study endpoint
R/R Non-Hodgkin Lymphoma NCT04639739
CD19
December 17, 2020 Phase I 9 Incidence of dose limiting toxicity
Incidence and severity of AEs and SAEs
Relapsed and Refractory B Cell Lymphoma NCT03692767
CD22
March 2019 Phase I 9 Occurrence of treatment related adverse events as assessed by CTCAE v4.0
Relapsed and Refractory B Cell Lymphoma NCT03690310
CD19
March 2019 Phase I 9 Occurrence of treatment related adverse events as assessed by CTCAE v4.0
Epithelial Ovarian Cancer NCT03692637
Mesothelin
March 2019 Phase I 30 Occurrence of treatment related adverse events as assessed by CTCAE v4.0
metastatic Solid Tumours NCT03415100
NKG2D-ligand
January 2, 2018 Phase I 30 Number of Adverse Events
Castration-Resistant Prostate Cancer NCT03692663
PSMA
December 2018 Phase I 9 Occurrence of treatment related adverse events as assessed by CTCAE v4.0
Solid Tumors NCT03940820
ROBO1
May 2019 Phase I/II 20 Occurrence of treatment related adverse events as assessed by CTCAE v4.03
Relapse/Refractory MM NCT03940833
BCMA
May 2019 Phase I/II 20 Occurrence of treatment related adverse events as assessed by CTCAE v4.03
Recurrent/Metastatic Gastric or Head and Neck Cancer NCT04847466
Irradiated PD-L1
April 22, 2021 Phase II 55 ORR
Relapsed and Refractory B Cell Lymphoma NCT03824964
CD19/CD22
February 1, 2019 Phase I 10 Occurrence of treatment related adverse events as assessed by CTCAE v4.0
B Lymphoid Malignancies NCT04796675
CD19
April 10, 2021 Phase I 27 Incidence of Treatment-related Adverse Events
Relapsed/Refractory CD33 + AML NCT02944162
CD33
October 2016 Phase I/II 10 Adverse events attributed to the administration of the anti-CD33 CAR-NK cells
CD19 Positive Leukemia and Lymphoma NCT02892695
CD19
September 2016 Phase I 10 Adverse events attributed to the administration of the anti-CD19 CAR-NK cells
Pancreatic Cancer NCT03941457
ROBO1
May 2019 Phase I 9 Occurrence of treatment related adverse events as assessed by CTCAE v4.03
CD19 + Relapsed/Refractory Hematological Malignancies NCT04796688
CD19
March 10, 2021 Phase I 27 Incidence of Treatment-related Adverse Events
Relapsed/Refractory B-Lymphoid Malignancies NCT03056339
CD19
June 21, 2017 Phase I/II 36 Toxicity and efficacy